Linear Clinical Research

What Linear Clinical Research does

Linear Clinical Research is a private, not-for-profit early-phase clinical trials site headquartered in Nedlands (Perth), Western Australia, operating as a wholly owned subsidiary of the Harry Perkins Institute of Medical Research. Founded in 2010, the organization operates four interconnected facilities, including the Advanced Clinical Trial Centre (ACTC), Australia's first licensed private hospital solely dedicated to next-generation clinical trials, alongside the Joondalup and Nedlands Clinical Trial Centres and the Hampden House administrative hub. Linear conducts Phase 1 through Phase 4 trials with deep specialization in first-in-human, healthy volunteer, oncology, and haematology studies, including CAR-T cell therapy and other cellular therapies, leveraging 66 healthy volunteer beds plus 18 ACTC beds with six overnight capabilities.

The company serves three primary customer segments: pharmaceutical and biotechnology sponsors seeking to run early-phase trials in Australia, healthy volunteers who participate in paid studies for compensation exceeding $500 per night, and cancer patients referred by medical specialists for access to cutting-edge therapies. Revenue is generated through negotiated per-trial professional services contracts with sponsors, supplemented by donations through its Deductible Gift Recipient status. Linear monetizes Australia's structural clinical trial advantages, including the TGA Clinical Trial Notification scheme (enabling start-up 4-6 months faster than US counterparts) and refundable R&D tax offsets of up to 43.5%, alongside internationally recognized Medical Directors in oncology and haematology, ICH-GCP/FDA/EMA compliance, and a 450+ trial track record with 126 publications in 2024.

Distribution is omnichannel: a dedicated business development team engages sponsors globally, world-renowned CRO partnerships extend reach, a self-serve online portal recruits from a 75,000+ volunteer database, and medical specialist referral networks funnel cancer patients to the ACTC. The organization is led by CEO Jayden Rogers with a full executive bench (CFO, CBDO, CPCTO) and governed by a Board chaired by Roger Port, including representatives of the parent Harry Perkins Institute and independent directors with Big Four and major healthcare backgrounds. Linear is positioned as Australia's leading early-phase clinical trial export platform, with operations concentrated in Western Australia but customer relationships spanning global pharma and biotech sponsors.

Name

Linear Clinical Research

Legal name

Linear Clinical Research Ltd

Website

https://linear.org.au

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Linear Clinical Research is a Perth-based not-for-profit early-phase clinical trials site, wholly owned by the Harry Perkins Institute of Medical Research, conducting first-in-human, healthy volunteer, oncology, and haematology studies for global pharmaceutical and biotech sponsors across four interconnected facilities.

Ownership category

akta.pro rank

Product category

Early-Phase Clinical Trial Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Clinical Research & Trial Central Laboratories (HLAFAMAL), Point-of-Care & Decentralized Trial Testing Services (HLAGAEAK)

Keywords

• Early phase clinical trials
• Clinical research services
• Oncology clinical trials
• Healthy volunteer studies
• First-in-human trials

Headquarters

HQ city

Perth

HQ country

Australia

HQ region

Oceania

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Clinical Trial Services for Sponsors: Linear generates revenue by conducting clinical trials on behalf of pharmaceutical and biotech sponsors. Services include Phase 1-4 trial management, protocol development, participant recruitment, and regulatory compliance support.
2. Participant Payments (Cost Recovery): Healthy volunteers are paid over $500 per night for participating in clinical trials. Payments vary based on trial length, visit frequency, and study complexity. Payments are approved by independent ethics committees.
3. Donations and Bequests: Tax-deductible donations from the public to support clinical research. All donations of $2 or more are tax-deductible in Australia. Linear is a registered Deductible Gift Recipient.

Pricing tiers

Go-to-market motion4 records

Distribution channels3 records

Marketing channels6 records

Core offering

Linear Clinical Research is a not-for-profit early-phase clinical trial provider operating four interconnected facilities in Perth, Western Australia. It executes Phase 1–4 trials for pharmaceutical and biotechnology sponsors, with core specialisation in first-in-human, healthy volunteer, oncology, and haematology studies. The company recruits participants through a 75,000+ volunteer database and medical specialist referrals, delivering ICH-GCP-compliant trials leveraging Australia's TGA Clinical Trial Notification scheme.

Product overview

Linear Clinical Research is a life-science organisation operating a unified clinical trial services platform consisting of four interconnected facilities (Advanced Clinical Trial Centre, Joondalup Clinical Trial Centre, Nedlands Clinical Trial Centre, and Hampden House) that deliver early-phase clinical trials spanning first-in-human, healthy volunteer, oncology, and haematology studies. The company offers a comprehensive service portfolio including Phase 1-4 trial conduct, participant screening and recruitment, cancer clinical trials with access to next-generation therapies including CAR-T cell therapy, and strategic protocol development for pharmaceutical and biotechnology sponsors. With over 15 years of experience, 450+ completed trials, and 420+ Phase 1/1b trials conducted, Linear positions itself as a purpose-driven organisation providing end-to-end clinical research services from concept to delivery.

Differentiator

Problem solved

Functional benefit

Products and services

• Early Phase Clinical Trials Phase 1 and 1b clinical trials executed for pharmaceutical and biotechnology sponsors, including first-in-human, first-in-patient, and early-phase studies across multiple therapeutic areas, conducted across Linear's three Perth facilities.
• Healthy Volunteer Clinical Trials Paid overnight and outpatient clinical trials for healthy adult volunteers aged 18+ conducted at the Joondalup and Nedlands facilities, with all meals, accommodation, and Wi-Fi included and per-night compensation exceeding AUD $500.
• Cancer Clinical Trials Oncology and haematology clinical trials including solid tumour, blood cancer, CAR-T cell therapy, and next-generation cellular therapies, delivered at the Advanced Clinical Trial Centre (ACTC) in Nedlands with 18 patient beds and six overnight capabilities.
• Strategic Project Planning and Protocol Development Strategic feasibility, project planning, protocol design, and rapid start-up services for Phase 1–4 sponsor trials, including regulatory submissions, site management, and quality assurance under TGA CTN scheme.
• Participant Screening Services Free health checks and comprehensive medical screening evaluations performed by doctors to determine participant eligibility for healthy volunteer and patient clinical trials, with AUD $100–$250 screening reimbursement where applicable.
• Oncology Patient Referral Service Referral pathway for medical specialists (oncologists and haematologists) to enrol cancer patients into Linear's oncology and haematology clinical trials, facilitated by Medical Directors Professor Michael Millward and Professor Chan Cheah.

Quantifiable outcome

• 94.5% cohorts dosed on time in FY24
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core, major, support and minor.

• Arrowhead PharmaceuticalscoreStrategic or Co-development PartnerArrowhead Pharmaceuticals has worked closely with Linear and Professor Gerald Watts across multiple phase I to III cardiometabolic clinical programs. Linear's world-class facilities and Australia's favourable regulatory environment have helped advance these important programs.
• SPARK at StanfordcoreStrategic or Co-development PartnerSPARK at Stanford collaborated with Linear on a clinical trial project. According to Professor Daria Mochley-Rosen, they were thoroughly impressed with the world-class service, excellent trial execution, and the project was completed ahead of schedule.
• Clinical Research Organisations (CROs)coreChannel Partner/ Reseller/ DistributorLinear partners with world-renowned Clinical Research Organisations in Australia to deliver high-quality, efficient trials. These trusted collaborations support global drug development across early and late-phase studies.
• Professor Michael MillwardcoreStrategic or Co-development PartnerInternationally recognised Medical Director for Oncology overseeing Linear's cancer clinical trials with driving excellence in clinical trials and ensuring highest standards of patient care.
• Professor Chan CheahcoreStrategic or Co-development PartnerInternationally recognised Medical Director for Haematology overseeing Linear's cancer clinical trials. Recognised among top 20 lymphoma researchers globally according to Expertscape. Founded Blood Cancer Research WA.
• Blood Cancer Research WAmajorStrategic or Co-development PartnerFounded by Professor Chan Cheah in 2018, BCRWA has transformed treatment of blood cancer patients and attracted outstanding researchers from around the world to deliver cutting-edge clinical trials for Western Australian patients.
• Medical Imaging and Diagnostic FacilitiessupportTechnology or IntegrationLinear collaborates with top medical imaging facilities to provide seamless access to PET Scanner (FDG/FLT), MRI, CT, X-ray, and other advanced diagnostic technologies for clinical trial participants.
• MedibankminorOthersCorporate health insurance partnership providing Linear employees with 9% discount on private health insurance, along with monthly wellbeing sessions via Medibank's Live Better series.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Syneos Health: Global biopharmaceutical services organisation offering clinical development and early-phase services; an established, broader-scope alternative to Linear for sponsors selecting site and CRO partners.
• IQVIA: Global clinical research services provider with extensive Phase 1 capacity and site relationships; competes for the same large pharma sponsor business that Linear pursues, but at global scale.
• ICON plc: Global CRO offering early-phase clinical research services among a broad portfolio; competes for biotech and pharma sponsors seeking early-phase execution but operates at significantly greater scale than Linear.
• Charles River Laboratories: Global CRO with established early-phase and discovery-to-clinical services; competes with Linear in early-stage sponsor mandates while operating a much broader services portfolio.

Direct peers

• Q-Pharm: Brisbane-based early-phase clinical trials facility with specialist Phase 1 capability in vaccines and infectious disease, overlapping directly with Linear's first-in-human and healthy volunteer service lines.
• CMAX Clinical Research: Adelaide-based early-phase clinical trial unit focused on first-in-human and healthy volunteer studies; directly comparable to Linear's Phase 1 core service offering and target sponsor base.
• Novotech: Australia-headquartered full-service CRO with strong early-phase and oncology capabilities across APAC; competes with Linear for sponsor trial placements and shares the Australia-as-trial-destination value proposition.
• Nucleus Network: Australian-headquartered early-phase clinical trial organisation operating Phase 1 units and healthy-volunteer programmes, directly comparable to Linear's specialist Phase 1, healthy volunteer, and oncology trial services in Australia.
• Scientia Clinical Research: Sydney-based early-phase clinical trial unit conducting Phase 1 trials across multiple therapeutic areas; competes with Linear for the same Australian pharma/biotech sponsor relationships.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/linearclinical
• LinkedInlinkedin.com/company/1050159
• Instagraminstagram.com/linear_clinical_research
• Xx.com/linearclinical

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Linear Clinical Research